Glucagon-like peptide-1, glucose homeostasis and diabetes.
about
Lixisenatide in type 2 diabetes: latest evidence and clinical usefulnessTherapy for obesity based on gastrointestinal hormonesOral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain TraumaVery short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.Neural and hormonal regulation of pancreatic secretion.Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trialEvidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy.Incretin therapy--present and future.Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.Exendin-4 decreases amphetamine-induced locomotor activity.Prior exercise does not alter the incretin response to a subsequent meal in obese womenThe glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in InsulinomaFuture detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.Effects of indigestible carbohydrates in barley on glucose metabolism, appetite and voluntary food intake over 16 h in healthy adults.Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated CardiomyopathyNor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion.Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-bConstructing bioactive peptides with pH-dependent activities.Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosingNear-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetesAcute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.Novel GLP-1 receptor agonists for diabetes.Potential cardiovascular effects of incretin-based therapies.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits.Incretin hormones and the satiation signal.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes.Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function.Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes MellitusOral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.Understanding GLP-1 analogs and enhancing patients success.
P2860
Q26771823-329D6AA0-EF2A-4087-BAC4-27717A9CCB53Q27006777-B597978E-91D5-4612-AA8D-AA54FE1C39F6Q28591252-FA7B70BA-E9FB-4D3F-8E8E-18481CA8FB1AQ30871457-9E8188B0-6AD5-4276-A151-BA7C3A30D403Q33726830-7830CB08-E9DF-42C2-8E6F-4A139F8B4E3AQ33728226-CCA7B366-3464-41A7-AC07-DD477BEA7E8EQ33784648-C6186C07-4EED-4BB7-B709-074C4AC2BAC7Q33786150-498A9940-3044-4E38-A856-34C3AD88B120Q34659509-EB266A4F-A89C-40F6-9AA2-B4363C84220FQ34745045-C158A58A-0F7F-4366-BDEF-ABF8DE7F4A48Q35558285-A631DDDA-70E9-4950-9AFA-55BCC74C475DQ35760283-7F1B50D1-69D2-4C44-B6A0-8E101CD3DAA3Q35910737-3AE82178-8E71-47A8-A15E-39D1B63FF440Q35948898-88EF9519-FF4E-42A1-B1A4-454082ACC91AQ36090308-73C2C6AB-24F2-4C7C-9AE2-1D1D5E87FDADQ36343957-D3288AB6-A77A-46AC-AF60-9FC6913FDC67Q36383709-451C5C8E-B866-41FF-A606-70D1EFFEF7B2Q36402230-DB9CC764-5643-4A53-A1E0-3EFA354876D3Q36742916-9371AD33-658E-4122-803F-69E7B86BDFD9Q36805409-A0BE5679-D511-4AEB-BB37-53A1DE4E30B6Q36939647-C900346D-2DD1-43AF-B513-858E61058A3DQ37173325-F5149484-C05B-42CE-9178-6627346D31AAQ37235875-6A18AD48-9689-45AF-A7F9-CDF720525221Q37326235-00F736B1-746C-4395-95A6-015B0B3201CBQ37364896-65872401-BF23-4E5F-9AF8-386C282231ADQ37631924-1EA9CDD4-99CF-4DB7-B5D5-DFEE6FAB9974Q37670232-A13C0907-B216-420F-A2A3-292F1E3228B4Q37960149-07E2E3F7-C7AC-417E-AC20-767EE96F9A3BQ37990619-00C1B98F-7FA1-410F-A438-1320E3449F5EQ38014516-96B6C8D2-973A-492C-A5F3-9FE0E0278BB8Q38030572-1EECD0F9-F533-45CC-AA7B-F56316A404BFQ38072203-AD3618C9-C48B-45B9-914E-87E907FC1BCBQ38126945-0425090A-A007-4D7F-A087-9E399E03077AQ38219482-E5A864DE-3184-450A-B1EA-105F5D7902E1Q38775771-85008746-DD02-4CFB-BA22-6ADBC9E464CDQ39419837-07F6226A-3161-4606-9F3B-72B362B7556EQ39842274-F621F78C-9A60-4E0F-8217-AADE524D21E3Q42279452-30E20092-84CC-464F-8BEF-E66EC56343CCQ42326757-EC24FBAD-D6B6-45BB-BDE6-10F6C36B6552Q42927083-0D645952-998C-48B1-822D-436DEB8E7842
P2860
Glucagon-like peptide-1, glucose homeostasis and diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@en
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@nl
type
label
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@en
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@nl
prefLabel
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@en
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@nl
P50
P1476
Glucagon-like peptide-1, glucose homeostasis and diabetes.
@en
P2093
Thure Krarup
P304
P356
10.1016/J.MOLMED.2008.01.003
P577
2008-03-18T00:00:00Z